A pathology perspective

Seminars in Breast Disease

Volumn 4, Issue 4, 2001, Pages 179-190

  Ioffe, O B ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CLINICAL PRACTICE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPH NODE BIOPSY; MAMMOGRAPHY; MEDICAL DECISION MAKING; METASTASIS; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SAMPLING; SENTINEL LYMPH NODE; TECHNIQUE;

EID: 0035660547     PISSN: 10924450     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Incidence of and treatment for ductal carcinoma in situ of the breast
2. Mammographic detection and staging of ductal carcinoma in situ: Mammographic-pathological correlation
3. Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer
4. Pathologic findings in nonpalpable invasive breast cancer
5. Margins of "lumpectomy" for breast cancer
6. Treatment of ductal carcinoma in situ
7. The relationship between shaved margin and inked margin status in breast excision specimens
8. Predictors of positive margins after local excision of ductal carcinoma in situ
9. Lumpectomy margins, reexcision, and local recurrence of breast cancer
10. Breast carcinomas of limited extent: Frequency, radiologic-pathologic characteristics, and surgical margin requirements
11. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy
12. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ
13. Duct carcinoma in situ: Biological implications for clinical practice
14. Noninvasive ductal carcinoma of the breast: The relevance of histologic categorization
15. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki- 67
16. Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X. Discriminants for tenth year treatment failure
17. Surgical treatment of ductal carcinoma in situ of the breast. 10- to 20-year follow-up
18. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures
19. Nonpalpable in situ ductal carcinoma of the breast. Predictors of multicentricity and microinvasion and implications for treatment
20. Heterogeneity of intraductal carcinoma of the breast
21. Microcalcifications associated with ductal carcinoma in situ: Mammographic-pathologic correlation
22. Pattern of distribution of intraductal and infiltrating ductal carcinoma: A three-dimensional study using serial coronal giant sections of the breast
23. Three dimensional imaging of mammary ductal carcinoma in situ: Clinical implications
24. Use of predictors of recurrence to plan therapy for DCIS of the breast
25. Consistency of histopathological reporting of breast lesions detected by screening: Findings of the U.K. National External Quality Assessment (EQA) Scheme
26. Pathologic and technical considerations in the treatment of ductal carcinoma in situ of the breast with lumpectomy and radiation therapy
27. Pathologic features of initial biopsy specimens associated with residual intraductal carcinoma on reexcision in patients with ductal carcinoma in situ of the breast referred for breast-conserving therapy
28. Application of the Van Nuys Prognostic Index in a retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macroscopic sectioning: Practical considerations
29. Predictors of local recurrence following excision alone for ductal carcinoma in situ
30. Neu overexpression correlates with extent of disease in large cell ductal carcinoma in situ of the breast
31. The influence of margin width on local control of ductal carcinoma in situ of the breast
32. The Consensus Conference on the treatment of in situ ductal carcinoma of the breast, April 22- 25, 1999
33. Can intraductal breast carcinoma be excised completely by local excision? Clinical and pathologic predictors
34. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: Intraductal carcinoma
35. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer
36. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
37. Does intraductal breast cancer spread in a segmental distribution? An analysis of residual tumour burden following segmental mastectomy using tumour bed biopsies
38. Local and distant failures after limited surgery with positive margins and radiotherapy for node-negative breast cancer
39. Breast-conserving therapy for macroscopically multiple cancers
40. An orientation to the concept of minimal carcinoma
41. Minimal breast cancer: An update
42. Management and survival of female patients with "minimal" breast cancer: As observed in the long-term and short-term surveys of the American College of Surgeons
43. Histopathology grading in small breast cancers < or = 10 mm-results from an area with mammography screening
44. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a, bN0M0): Clinicopathologic features and outcome
45. Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0)
46. Factors influencing survival and prognosis in early breast carcinoma (T1N0M0-T1N1M0). Assessment of 644 patients with median follow-up of 18 years
47. Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up
48. Microinvasive breast carcinoma: Clinicopathologic analysis of a single institution experience
49. Observations on the histopathologic diagnosis of microinvasive carcinoma of the breast
50. Mammary ductal carcinoma in situ with microinvasion
51. Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma
52. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999
53. Relationship of the size of the invasive component of the primary breast carcinoma to axillary lymph node metastasis
54. Correlation of tumor size with lymph node status in multifocal breast carcinoma
55. Predictors of breast recurrence after conservative surgery and radiation therapy for invasive breast cancer
56. Pathologic predictors of early local recurrence in Stage I and II breast cancer treated by primary radiation therapy
57. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no. 4). I. Observations concerning the multicentricity of mammary cancer
58. Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma
59. Ductal carcinoma of the breast. An analysis of proportions of intraductal and invasive components
60. Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy
61. The influence of age and extensive intraductal component histology upon breast lumpectomy margin assessment as a predictor of residual tumor
62. Impact of extensive intraductal component on recurrence and survival in patients with stage I or II breast cancer treated with breast conservation therapy
63. Ten year results of a randomised trial comparing two conservative treatment strategies for small size breast cancer
64. Resection margin status in lumpectomy specimens of infiltrating lobular carcinoma
65. Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy
66. The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy
67. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants
68. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4)
69. The radiation oncology perspective
70. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: Reevaluation with longer follow-up
71. Occult axillary node metastases in breast cancer: Their detection and prognostic significance
72. Breast cancer: Two micrometastatic variants in the axilla that differ in prognosis
73. Occult axillary lymph node metastases from breast cancers with intramammary lymphatic tumor emboli
74. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy
75. "Missed" micrometastases - The extent of the problem
76. Pathologic correlates of prognosis in lymph node-positive breast carcinomas
77. Axillarv micro- and macrometastases in breast cancer: Prognostic significance tumor size
78. The significance of breast cancer lymph node micrometastases
79. Occult axillary lymph node metastases in ¢node-negative" breast carcinoma
80. Immunohistochemical detection and significance of axillary lymph node micrometastases in breast carcinoma
81. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer
82. Management of the axilla in operable breast: Cancer treated by breast conservation: A randomized clinical trial
83. Occult metastases in breast cancer are more likely to be detected in sentinel lymph nodes than in non-sentinel lymph nodes
84. Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging
85. Comparison of different histopathological methods for the examination of sentinel lymph nodes in breast cancer
86. Rapid immunohistochemistry for cytokeratin in the intraoperative evaluation of sentinel lymph nodes in breast cancer patients
87. Intraoperative examination of the sentinel lymph node for breast carcinoma staging
88. Radioguided sentinel node biopsy to avoid axillary dissection in breast cancer
89. Completion axillary dissection in breast cancer patients with sentinel node positive for micrometastases
90. Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer
91. The significance of extracapsular extension of axillary lymph node metastases in early-stage breast cancer
92. Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ
93. Predicting the likelihood of residual disease in women treated for ductal carcinoma in situ
94. Follow-up of two treatment modalities for ductal cancer in situ of the breast
95. Carcinoma in situ of the female breast. 10 Year follow-up results of a prospective nationwide study
96. Relationship between the size and margin status of ductal carcinoma in situ of the breast and residual disease
97. Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-conserving therapy
98. Relationship between excision volume, margin status, and tumor size with the development of local recurrence in patients with ductal carcinoma-in-situ treated with breast-conserving therapy
99. Cancerization of lobules and atypical ductal hyperplasia adjacent to ductal carcinoma in situ of the breast
100. Ipsilateral local recurrence in relation to therapy and morphological characteristics in patients with ductal carcinoma in situ of the breast